Pilot corpus: NIH-funded biomedical datasets. Any DOI can be scored on demand — network effects sharpen as coverage grows.

A multicenter report of the use of plasma rich in growth factors (PRGF) for the treatment of patients with ocular surface diseases in North America

The Ocular Surface(2022)10.1016/j.jtos.2022.04.007Source: DataRank Database

A multicenter report of the use of plasma rich in growth factors (PRGF) for the treatment of patients with ocular surface diseases in North America is a research paper published in The Ocular Surface (2022). On theSindex it has a DataRank of 0. It has been cited 30 times.

N/A

0DataRank · unranked

Scored on demand from live citation data

30 citations

Free full text

Cite:

DataRank reads this dataset's downstream impact straight off the citation graph — no black box, no proprietary weighting. How is this computed?

›Methodology & internals

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Pipeline:MetadataData-paper checkEnrichmentCitation networkScoring

Enrichment:Funding (9 grants)Impact (FWCI 5.24)OA: closedTopics (44)IDs (PubMed, OpenAlex)

FAIR Checklist

Context only (not used in score)

Findable (1/2)

Has DOI

Accessible (0/2)

Interoperable (0/2)

Reusable (0/3)

FAIR checklist signals are shown for context only and do not affect DataRank scoring.

Run a calibrated FAIR evaluation for this paper →

We only score data papers we can read in full — never from an abstract alone.

Authors (8)

Arianna Tovar ORCID,Margaret Wang ORCID,Hazem M. Mousa ORCID,Sowmya Yennam,Alfonso L. Sabater ORCID

Live enrichment

PubMed:35489588 OpenAlex:https://openalex.org/W4225255139

National Institutes of Health

Grant: P30EY014801

National Eye Institute

Grant: R01EY024485

National Eye Institute

Grant: R01EY030283

Research to Prevent Blindness

Hamill Foundation

Sid W. Richardson Foundation

Beauty of Sight Foundation

GlaxoSmithKline

Eye Bank Association of America

FWCI

5.24

Citation Percentile

1.0%

Citation Trend

2022

2023

2024

2025

2026

closedLicense: https://doi.org/10.15223/policy-004

publisherhttps://api.elsevier.com/content/article/PII:S1542012422000350?httpAccept=text/xml

publisherhttps://api.elsevier.com/content/article/PII:S1542012422000350?httpAccept=text/plain

journalhttps://doi.org/10.1016/j.jtos.2022.04.007

repositoryhttps://pubmed.ncbi.nlm.nih.gov/35489588

Fields of Study

Ocular Surface and Contact LensCorneal Surgery and TreatmentsPeriodontal Regeneration and TreatmentsAgedAged, 80 and overCorneaDry Eye SyndromesFemaleHumansIntercellular Signaling Peptides and ProteinsMaleMiddle AgedOphthalmic SolutionsPlasma

MeSH Terms

AgedAged, 80 and overCorneaFemaleHumansMaleMiddle AgedOphthalmic SolutionsPlasmaDry Eye SyndromesIntercellular Signaling Peptides and Proteins

Keywords

MedicineCohortMulticenter studyAdverse effectPopulationCohort studyOphthalmologyInternal medicineRandomized controlled trialCorneaPrPCorneal UlcerDry EyePrgfOcular Surfacelimbal stem cell deficiencyPlasma Rich In Growth FactorsNeurotrophic KeratopathyPlatelet Rich Plasma Therapy

A multicenter report of the use of plasma rich in growth factors (PRGF) for the treatment of patients with ocular surface diseases in North America

FAIR Checklist

Authors (8)

Funding (9 grants)

Impact

Open Access

Topics